

James B Rowe Frcp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1060989/publications.pdf>

Version: 2024-02-01

357
papers

25,237
citations

6254

80
h-index

11607

135
g-index

437
all docs

437
docs citations

437
times ranked

23784
citing authors

#	ARTICLE	IF	CITATIONS
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	1.2	18
2	FRONTotemporal dementia Incidence European Research Studyâ€”FRONTIERS: Rationale and design. <i>Alzheimer's and Dementia</i> , 2022, 18, 498-506.	0.8	12
3	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	1.9	7
4	Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study. <i>Brain</i> , 2022, 145, 340-348.	7.6	21
5	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 336-339.	1.9	1
6	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
7	Proton magnetic resonance spectroscopy in frontotemporal lobar degeneration-related syndromes. <i>Neurobiology of Aging</i> , 2022, 111, 64-70.	3.1	10
8	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
9	InÂVivo ¹⁸F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1052-1057.	5.0	9
10	Neurophysiological and Brain Structural Markers of Cognitive Frailty Differ from Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2022, 42, 1362-1373.	3.6	13
11	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
12	Dynamic targeting enables domain-general inhibitory control over action and thought by the prefrontal cortex. <i>Nature Communications</i> , 2022, 13, 274.	12.8	32
13	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	2.6	3
14	Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimerâ€™s disease, frontotemporal dementia and progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 651-658.	1.9	64
15	Prediagnostic Progressive Supranuclear Palsy â€” Insights from the UK Biobank. <i>Parkinsonism and Related Disorders</i> , 2022, 95, 59-64.	2.2	7
16	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
17	Dataâ€”driven staging of genetic frontotemporal dementia using multiâ€”modal <scp>MRI</scp>. <i>Human Brain Mapping</i> , 2022, 43, 1821-1835.	3.6	7
18	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.8	24

#	ARTICLE	IF	CITATIONS
19	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
20	Causal Evidence for the Multiple Demand Network in Change Detection: Auditory Mismatch Magnetoencephalography across Focal Neurodegenerative Diseases. <i>Journal of Neuroscience</i> , 2022, 42, 3197-3215.	3.6	14
21	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. <i>Journal of Neurology</i> , 2022, 269, 4322-4332.	3.6	1
22	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	3.7	1
23	Prefrontal Cortical Connectivity Mediates Locus Coeruleus Noradrenergic Regulation of Inhibitory Control in Older Adults. <i>Journal of Neuroscience</i> , 2022, 42, 3484-3493.	3.6	16
24	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i>-associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771.	1.9	12
25	A â€˜Mini Linguistic State Examinationâ€™™ to classify primary progressive aphasia. <i>Brain Communications</i> , 2022, 4, fcab299.	3.3	15
26	The pre-supplementary motor area achieves inhibitory control by modulating response thresholds. <i>Cortex</i> , 2022, 152, 98-108.	2.4	8
27	Heteroplasmic mitochondrial DNA mutations in frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2022, 143, 687-695.	7.7	22
28	Noradrenergic deficits contribute to apathy in Parkinsonâ€™s disease through the precision of expected outcomes. <i>PLoS Computational Biology</i> , 2022, 18, e1010079.	3.2	19
29	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.1	5
30	Locus Coeruleus Integrity from <scp>7â€‰%T MRI</scp> Relates to Apathy and Cognition in Parkinsonian Disorders. <i>Movement Disorders</i> , 2022, 37, 1663-1672.	3.9	23
31	A synergistic core for human brain evolution and cognition. <i>Nature Neuroscience</i> , 2022, 25, 771-782.	14.8	80
32	A multi-site, multi-participant magnetoencephalography resting-state dataset to study dementia: The BioFIND dataset. <i>NeuroImage</i> , 2022, 258, 119344.	4.2	7
33	Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimerâ€™s disease: systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1080-1090.	1.9	24
34	The effects of age on restingâ€ˆstate BOLD signal variability is explained by cardiovascular and cerebrovascular factors. <i>Psychophysiology</i> , 2021, 58, e13714.	2.4	51
35	Relationship between tau, neuroinflammation and atrophy in Alzheimer's disease: The NIMROD study. <i>Information Fusion</i> , 2021, 67, 116-124.	19.1	18
36	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. <i>Movement Disorders</i> , 2021, 36, 503-508.	3.9	15

#	ARTICLE	IF	CITATIONS
37	Neuroanatomical substrates of generalized brain dysfunction in COVID-19. Intensive Care Medicine, 2021, 47, 116-118.	8.2	31
38	The revised Addenbrooke's Cognitive Examination can facilitate differentiation of dementia with Lewy bodies from Alzheimer's disease. International Journal of Geriatric Psychiatry, 2021, 36, 831-838.	2.7	3
39	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56
40	Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography. Neurobiology of Aging, 2021, 101, 172-180.	3.1	14
41	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
42	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
43	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.8	31
44	An in vivo probabilistic atlas of the human locus coeruleus at ultra-high field. NeuroImage, 2021, 225, 117487.	4.2	50
45	In vivo PET imaging of neuroinflammation in familial frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 319-322.	1.9	21
46	In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 45-52.	1.9	38
47	In Vivo Assay of Cortical Microcircuitry in Frontotemporal Dementia: A Platform for Experimental Medicine Studies. Cerebral Cortex, 2021, 31, 1837-1847.	2.9	19
48	Language impairment in progressive supranuclear palsy and corticobasal syndrome. Journal of Neurology, 2021, 268, 796-809.	3.6	41
49	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
50	Looking beneath the surface: the importance of subcortical structures in frontotemporal dementia. Brain Communications, 2021, 3, fcab158.	3.3	22
51	Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. Brain Communications, 2021, 3, fcab206.	3.3	12
52	[18F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases. Brain Communications, 2021, 3, fcab177.	3.3	2
53	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
54	Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 737-744.	1.9	18

#	ARTICLE	IF	CITATIONS
55	Advances in neuroimaging to support translational medicine in dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 263-270.	1.9	12
56	Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease. Brain, 2021, 144, 2513-2526.	7.6	53
57	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	1.9	10
58	GABAergic cortical network physiology in frontotemporal lobar degeneration. Brain, 2021, 144, 2135-2145.	7.6	24
59	The role of noradrenaline in cognition and cognitive disorders. Brain, 2021, 144, 2243-2256.	7.6	81
60	Neuroinflammation predicts disease progression in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 769-775.	1.9	40
61	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.1	52
62	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
63	Dementia wellbeing and COVID-19: Review and expert consensus on current research and knowledge gaps. International Journal of Geriatric Psychiatry, 2021, 36, 1597-1639.	2.7	52
64	In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies. Neurobiology of Aging, 2021, 101, 187-198.	3.1	17
65	A case report of metastatic renal cell carcinoma causing corticobasal syndrome. , 2021, 40, 160-164.		0
66	Characterizing the Clinical Features and Atrophy Patterns of <i>MAPT</i> -Related Frontotemporal Dementia With Disease Progression Modeling. Neurology, 2021, 97, e941-e952.	1.1	29
67	Synaptic density in carriers of C9orf72 mutations: a ¹¹ CUCB PET study. Annals of Clinical and Translational Neurology, 2021, 8, 1515-1523.	3.7	27
68	Progressive supranuclear palsy: diagnosis and management. Practical Neurology, 2021, 21, 376-383.	1.1	12
69	Evidence and implications of abnormal predictive coding in dementia. Brain, 2021, 144, 3311-3321.	7.6	22
70	Language Disorder in Progressive Supranuclear Palsy and Corticobasal Syndrome: Neural Correlates and Detection by the MLSE Screening Tool. Frontiers in Aging Neuroscience, 2021, 13, 675739.	3.4	11
71	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
72	The Dementia UK Ecosystem: a call to action. Lancet Neurology, The, 2021, 20, 699-700.	10.2	2

#	ARTICLE	IF	CITATIONS
73	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chroconnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
74	Co-Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1225-1233.	1.5	6
75	Functional localization and categorization of intentional decisions in humans: A meta-analysis of brain imaging studies. <i>NeuroImage</i> , 2021, 242, 118468.	4.2	16
76	Altered network stability in progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2021, 107, 109-117.	3.1	8
77	Altered structural connectivity networks in dementia with lewy bodies. <i>Brain Imaging and Behavior</i> , 2021, 15, 2445-2453.	2.1	8
78	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28
79	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8
80	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	3.9	13
81	Separating vascular and neuronal effects of age on fMRI BOLD signals. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2021, 376, 20190631.	4.0	77
82	In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease. <i>Science Advances</i> , 2021, 7, eabh1448.	10.3	70
83	Are the UK genetic testing criteria for dementia too exclusive?. <i>Journal of Neurology</i> , 2021, , 1.	3.6	0
84	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	10.8	9
85	Physical Activity Predicts Population-Level Age-Related Differences in Frontal White Matter. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 236-243.	3.6	22
86	Validation of the Movement Disorder Society Criteria for the Diagnosis of Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	3.9	37
87	18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2020, 267, 341-349.	3.6	21
88	Cognitive Diversity in a Healthy Aging Cohort: Cross-Domain Cognition in the Cam-CAN Project. <i>Journal of Aging and Health</i> , 2020, 32, 1029-1041.	1.7	15
89	Editorial. <i>Brain</i> , 2020, 143, 1-1.	7.6	5
90	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020, 77, 377.	9.0	94

#	ARTICLE	IF	CITATIONS
91	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	175
92	Falls in Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 16-24.	1.5	16
93	Effect of apolipoprotein E polymorphism on cognition and brain in the Cambridge Centre for Ageing and Neuroscience cohort. <i>Brain and Neuroscience Advances</i> , 2020, 4, 239821282096170.	3.4	17
94	Synaptic Loss in Primary Tauopathies Revealed by [¹¹ C]UCBâ€” Positron Emission Tomography. <i>Movement Disorders</i> , 2020, 35, 1834-1842.	3.9	61
95	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984.	1.9	25
96	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1325-1328.	1.9	12
97	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	3.3	4
98	Towards accurate and unbiased imaging-based differentiation of Parkinsonâ€™s disease, progressive supranuclear palsy and corticobasal syndrome. <i>Brain Communications</i> , 2020, 2, fcaa051.	3.3	14
99	GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition. <i>Brain</i> , 2020, 143, 3449-3462.	7.6	55
100	Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy. <i>Annals of Neurology</i> , 2020, 88, 1194-1204.	5.3	38
101	<i>C9orf72</i> , age at onset, and ancestry help discriminate behavioral from language variants in FTL cohorts. <i>Neurology</i> , 2020, 95, e3288-e3302.	1.1	7
102	Clinical Conditions â€”Suggestive of Progressive Supranuclear Palsyâ€”Diagnostic Performance. <i>Movement Disorders</i> , 2020, 35, 2301-2313.	3.9	22
103	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. <i>Brain Communications</i> , 2020, 2, .	3.3	20
104	Noradrenergic contributions to cognitive decline and treatment potential in progressive supranuclear palsy and Parkinsonâ€™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044767.	0.8	0
105	Multi-centre, multi-vendor reproducibility of 7T QSM and R2* in the human brain: Results from the UK7T study. <i>NeuroImage</i> , 2020, 223, 117358.	4.2	20
106	Microglial activation and tau burden predict cognitive decline in Alzheimerâ€™s disease. <i>Brain</i> , 2020, 143, 1588-1602.	7.6	113
107	GABA-ergic Dynamics in Human Frontotemporal Networks Confirmed by Pharmac-Magnetoencephalography. <i>Journal of Neuroscience</i> , 2020, 40, 1640-1649.	3.6	27
108	Gray matter changes related to microglial activation in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 236-242.	3.1	13

#	ARTICLE	IF	CITATIONS
109	Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. <i>Brain</i> , 2020, 143, 1010-1026.	7.6	68
110	Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics. <i>Neurobiology of Aging</i> , 2020, 92, 141-152.	3.1	34
111	Correlation of microglial activation with white matter changes in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2020, 25, 102200.	2.7	17
112	Alien limb syndrome: A Bayesian account of unwanted actions. <i>Cortex</i> , 2020, 127, 29-41.	2.4	14
113	Age-related reduction in motor adaptation: brain structural correlates and the role of explicit memory. <i>Neurobiology of Aging</i> , 2020, 90, 13-23.	3.1	42
114	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 263-270.	1.9	106
115	Anterior temporal lobe is necessary for efficient lateralised processing of spoken word identity. <i>Cortex</i> , 2020, 126, 107-118.	2.4	19
116	Alien limb in the corticobasal syndrome: phenomenological characteristics and relationship to apraxia. <i>Journal of Neurology</i> , 2020, 267, 1147-1157.	3.6	11
117	Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity. <i>Acta Neuropathologica Communications</i> , 2020, 8, 11.	5.2	24
118	Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences. <i>Nature Communications</i> , 2020, 11, 1712.	12.8	74
119	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	1.9	55
120	The Dementias Platform UK (DPUK) Data Portal. <i>European Journal of Epidemiology</i> , 2020, 35, 601-611.	5.7	45
121	Metabolomic changes associated with frontotemporal lobar degeneration syndromes. <i>Journal of Neurology</i> , 2020, 267, 2228-2238.	3.6	12
122	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	5.3	19
123	Peak Width of Skeletonized Mean Diffusivity as a Marker of Diffuse Cerebrovascular Damage. <i>Frontiers in Neuroscience</i> , 2020, 14, 238.	2.8	24
124	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	2.4	26
125	Apathy is associated with reduced precision of prior beliefs about action outcomes.. <i>Journal of Experimental Psychology: General</i> , 2020, 149, 1767-1777.	2.1	15
126	Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. <i>Brain</i> , 2020, 143, 1555-1571.	7.6	94

#	ARTICLE	IF	CITATIONS
127	11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies. European Journal of Hybrid Imaging, 2020, 4, 25.	1.5	18
128	Cortical Complexity Analyses and Their Cognitive Correlate in Alzheimer's Disease and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 76, 331-340.	2.6	31
129	Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies. International Journal of Clinical Pharmacology and Therapeutics, 2020, 58, 426-438.	0.6	14
130	Editorial. Brain, 2020, 143, 381-382.	7.6	0
131	Clinicopathological co-occurrence of Fahr's disease and dementia with Lewy bodies. , 2020, 39, 227-231.		2
132	European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 538-549.	2.4	17
133	Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 450-462.	2.4	24
134	Connectomics and molecular imaging in neurodegeneration. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2819-2830.	6.4	21
135	Tackling gaps in developing life-changing treatments for dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 241-253.	3.7	17
136	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 2019, 142, 2558-2571.	7.6	219
137	Neuroinflammation and Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance. Journal of Neuroscience, 2019, 39, 7218-7226.	3.6	145
138	Test Your Memory (TYM test): diagnostic evaluation of patients with non-Alzheimer dementias. Journal of Neurology, 2019, 266, 2546-2553.	3.6	8
139	Atomoxetine and citalopram alter brain network organization in Parkinson's disease. Brain Communications, 2019, 1, fcz013.	3.3	10
140	Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid-positive mild cognitive impairment is associated with key clinical features. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 690-699.	2.4	26
141	11 C- ¹¹ PK11195 PET imaging and white matter changes in Parkinson's disease dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2133-2136.	3.7	9
142	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
143	Test Your Memory (TYM) and Test Your Memory for Mild Cognitive Impairment (TYM-MCI): A Review and Update Including Results of Using the TYM Test in a General Neurology Clinic and Using a Telephone Version of the TYM Test. Diagnostics, 2019, 9, 116.	2.6	10
144	Evidence of a Causal Association Between Cancer and Alzheimer's Disease: a Mendelian Randomization Analysis. Scientific Reports, 2019, 9, 13548.	3.3	26

#	ARTICLE	IF	CITATIONS
145	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
146	Inflammation and cerebral small vessel disease: A systematic review. <i>Ageing Research Reviews</i> , 2019, 53, 100916.	10.9	213
147	Education modulates brain maintenance in presymptomatic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1124-1130.	1.9	23
148	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019, 9, e024498.	1.9	18
149	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	3.9	93
150	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 768-773.	1.9	29
151	Meta-analytic Evidence for the Plurality of Mechanisms in Transdiagnostic Structural MRI Studies of Hallucination Status. <i>EClinicalMedicine</i> , 2019, 8, 57-71.	7.1	29
152	Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration. <i>Neurology</i> , 2019, 92, e1547-e1557.	1.1	42
153	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2019, 142, 1108-1120.	7.6	41
154	In vivo evidence for pre-symptomatic neuroinflammation in a <i>MAPT</i> mutation carrier. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 373-378.	3.7	27
155	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309.	2.4	30
156	ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid β 2 copathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 277-280.	2.4	24
157	Disease-informed brain mapping teaches important lessons about the human brain. <i>NeuroImage</i> , 2019, 190, 1-3.	4.2	0
158	Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. <i>Neurology</i> , 2019, 93, e1699-e1706.	1.1	19
159	Parkinsonism in frontotemporal dementias. <i>International Review of Neurobiology</i> , 2019, 149, 249-275.	2.0	24
160	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
161	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. <i>NeuroImage</i> , 2019, 188, 282-290.	4.2	16
162	Strong and specific associations between cardiovascular risk factors and white matter micro- and macrostructure in healthy aging. <i>Neurobiology of Aging</i> , 2019, 74, 46-55.	3.1	38

#	ARTICLE	IF	CITATIONS
163	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019, 77, 169-177.	3.1	47
164	Imaging Tau, Neuroinflammation, and A β in Dementia With Lewy Bodies: A Deepâ€œPhenotyping Case Report. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 77-80.	1.5	3
165	Gait in Mild Alzheimerâ€™s Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 331-341.	2.6	42
166	White matter change with apathy and impulsivity in frontotemporal lobar degeneration syndromes. <i>Neurology</i> , 2018, 90, e1066-e1076.	1.1	31
167	Neurotransmitter deficits from frontotemporal lobar degeneration. <i>Brain</i> , 2018, 141, 1263-1285.	7.6	129
168	Tau burden and the functional connectome in Alzheimerâ€™s disease and progressive supranuclear palsy. <i>Brain</i> , 2018, 141, 550-567.	7.6	190
169	Longitudinal diffusion tensor imaging changes in early Parkinsonâ€™s disease: ICICLE-PD study. <i>Journal of Neurology</i> , 2018, 265, 1528-1539.	3.6	35
170	[¹¹ C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. <i>Neurology</i> , 2018, 90, e1989-e1996.	1.1	89
171	Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 131-140.	3.4	41
172	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 191-196.	3.1	151
173	[¹⁸ F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1032-1037.	1.9	77
174	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 245.e9-245.e12.	3.1	40
175	Neuroticism predicts the impact of serotonin challenges on fear processing in subgenual anterior cingulate cortex. <i>Scientific Reports</i> , 2018, 8, 17889.	3.3	12
176	Early microglial activation and peripheral inflammation in dementia with Lewy bodies. <i>Brain</i> , 2018, 141, 3415-3427.	7.6	95
177	In-vivo coupling of tau pathology and cortical thinning in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 678-687.	2.4	24
178	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	7.6	39
179	Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans. <i>Neuropsychopharmacology</i> , 2018, 43, 2645-2651.	5.4	72
180	Sensory attenuation in Parkinsonâ€™s disease is related to disease severity and dopamine dose. <i>Scientific Reports</i> , 2018, 8, 15643.	3.3	30

#	ARTICLE	IF	CITATIONS
181	[¹⁸ F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1292-1296.	3.7	19
182	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. <i>Nature Communications</i> , 2018, 9, 4273.	12.8	263
183	Predict Disease Progression With Reaction Rate Equation Modeling of Multimodal MRI and PET. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 306.	3.4	2
184	A β 42/A β 40 and A β 42/A β 38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1377-1383.	2.6	23
185	Reply: Brain oscillations, inhibition and social inappropriateness in frontotemporal degeneration. <i>Brain</i> , 2018, 141, e74-e74.	7.6	1
186	Activity and Connectivity Differences Underlying Inhibitory Control Across the Adult Life Span. <i>Journal of Neuroscience</i> , 2018, 38, 7887-7900.	3.6	69
187	Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus phenotype. <i>Brain</i> , 2018, 141, 2500-2510.	7.6	60
188	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 46.	6.2	34
189	Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia. <i>Brain</i> , 2018, 141, 2486-2499.	7.6	64
190	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1025-1036.	3.7	39
191	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1-16.	2.6	28
192	Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2017, 29, 545-555.	1.0	56
193	Parsing the Roles of the Frontal Lobes and Basal Ganglia in Task Control Using Multivoxel Pattern Analysis. <i>Journal of Cognitive Neuroscience</i> , 2017, 29, 1390-1401.	2.3	4
194	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	3.9	121
195	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.	3.9	179
196	Apathy and impulsivity in frontotemporal lobar degeneration syndromes. <i>Brain</i> , 2017, 140, 1792-1807.	7.6	109
197	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2017, 140, 1784-1791.	7.6	55
198	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402

#	ARTICLE	IF	CITATIONS
199	Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. <i>BMJ Open</i> , 2017, 7, e013187.	1.9	65
200	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. <i>NeuroImage: Clinical</i> , 2017, 15, 171-180.	2.7	63
201	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 55, 78-90.	3.1	48
202	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , 2017, 32, 510-525.	3.9	92
203	In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. <i>Ageing Research Reviews</i> , 2017, 36, 50-63.	10.9	107
204	Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 115-122.	1.5	28
205	An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease. <i>Journal of Neurology</i> , 2017, 264, 2457-2463.	3.6	21
206	Artificial grammar learning in vascular and progressive non-fluent aphasia. <i>Neuropsychologia</i> , 2017, 104, 201-213.	1.6	27
207	The Test Your Memory for Mild Cognitive Impairment (TYM-MCI). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 1045-1051.	1.9	10
208	Hippocampal Stratum Radiatum, Lacunosum, and Molecular Sparing in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 415-424.	2.6	27
209	[P4 ¹⁸⁹]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1337.	0.8	2
210	Genetic screening in sporadic ALS and FTD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 1042-1044.	1.9	105
211	Cognitive Training Using a Novel Memory Game on an iPad in Patients with Amnesic Mild Cognitive Impairment (aMCI). <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 624-633.	2.1	100
212	¹⁸ F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. <i>Brain</i> , 2017, 140, aww340.	7.6	174
213	Evidence for causal top-down frontal contributions to predictive processes in speech perception. <i>Nature Communications</i> , 2017, 8, 2154.	12.8	107
214	PET Tau and Amyloid- β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 283-293.	2.6	67
215	iElectrodes: A Comprehensive Open-Source Toolbox for Depth and Subdural Grid Electrode Localization. <i>Frontiers in Neuroinformatics</i> , 2017, 11, 14.	2.5	58
216	Under pressure: is there a link between orthostatic hypotension and cognitive impairment in α -synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1311-1321.	1.9	75

#	ARTICLE	IF	CITATIONS
217	Neuroinflammatory and morphological changes in late-life depression: the NIMROD study. British Journal of Psychiatry, 2016, 209, 525-526.	2.8	59
218	[¹⁸ F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. Annals of Clinical and Translational Neurology, 2016, 3, 940-947.	3.7	41
219	Managing cognition in progressive supranuclear palsy. Neurodegenerative Disease Management, 2016, 6, 499-508.	2.2	32
220	Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology, 2016, 86, 1736-1743.	1.1	383
221	Network mechanisms of intentional learning. NeuroImage, 2016, 127, 123-134.	4.2	39
222	Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. Neurobiology of Aging, 2016, 48, 153-160.	3.1	79
223	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Movement Disorders, 2016, 31, 1062-1066.	3.9	59
224	Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease. Movement Disorders, 2016, 31, 1163-1172.	3.9	20
225	Ageing increases reliance on sensorimotor prediction through structural and functional differences in frontostriatal circuits. Nature Communications, 2016, 7, 13034.	12.8	101
226	Atomoxetine restores the response inhibition network in Parkinson's disease. Brain, 2016, 139, 2235-2248.	7.6	76
227	Convergent evidence for hierarchical prediction networks from human electrocorticography and magnetoencephalography. Cortex, 2016, 82, 192-205.	2.4	71
228	Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease. Brain, 2016, 139, 161-173.	7.6	88
229	Extrinsic and Intrinsic Brain Network Connectivity Maintains Cognition across the Lifespan Despite Accelerated Decay of Regional Brain Activation. Journal of Neuroscience, 2016, 36, 3115-3126.	3.6	185
230	Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Human Brain Mapping, 2016, 37, 1026-1037.	3.6	60
231	Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease. Neuropsychopharmacology, 2016, 41, 2171-2177.	5.4	43
232	The basal ganglia in cognitive disorders. , 2016, , 69-80.		4
233	Idiosyncratic responding during movie-watching predicted by age differences in attentional control. Neurobiology of Aging, 2015, 36, 3045-3055.	3.1	74
234	A Winding Road: Alzheimer's Disease Increases Circuitous Functional Connectivity Pathways. Frontiers in Computational Neuroscience, 2015, 9, 140.	2.1	12

#	ARTICLE	IF	CITATIONS
235	Dopaminergic modulation of positive expectations for goal-directed action: evidence from Parkinson's disease. <i>Frontiers in Psychology</i> , 2015, 6, 1514.	2.1	14
236	Editorial. <i>Brain</i> , 2015, 138, 505-506.	7.6	0
237	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. <i>Lancet Neurology</i> , The, 2015, 14, 253-262.	10.2	432
238	The neural signature of information regularity in temporally extended event sequences. <i>NeuroImage</i> , 2015, 107, 266-276.	4.2	11
239	Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 141-149.	3.9	84
240	The Prefrontal Cortex Achieves Inhibitory Control by Facilitating Subcortical Motor Pathway Connectivity. <i>Journal of Neuroscience</i> , 2015, 35, 786-794.	3.6	184
241	The effect of ageing on fMRI: Correction for the confounding effects of vascular reactivity evaluated by joint fMRI and MEG in 335 adults. <i>Human Brain Mapping</i> , 2015, 36, 2248-2269.	3.6	169
242	Improving response inhibition systems in frontotemporal dementia with citalopram. <i>Brain</i> , 2015, 138, 1961-1975.	7.6	71
243	Hierarchical Organization of Frontotemporal Networks for the Prediction of Stimuli across Multiple Dimensions. <i>Journal of Neuroscience</i> , 2015, 35, 9255-9264.	3.6	92
244	Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , 2015, 138, 2974-2986.	7.6	188
245	Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. <i>Neurobiology of Aging</i> , 2015, 36, 1519-1528.	3.1	35
246	Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans. <i>Brain</i> , 2015, 138, 1658-1666.	7.6	65
247	The role of the amygdala during emotional processing in Huntington's disease: From pre-manifest to late stage disease. <i>Neuropsychologia</i> , 2015, 70, 80-89.	1.6	41
248	The Mini-Addenbrooke's Cognitive Examination: A New Assessment Tool for Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 1-11.	1.5	202
249	Neuroinflammation in Lewy body dementia. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1398-1406.	2.2	68
250	Editorial. <i>Brain</i> , 2015, 138, 2461-2462.	7.6	1
251	Improving Response Inhibition in Parkinson's Disease with Atomoxetine. <i>Biological Psychiatry</i> , 2015, 77, 740-748.	1.3	93
252	Disorders of Volition from Neurological Disease. , 2015, , 389-414.		4

#	ARTICLE	IF	CITATIONS
253	Multiple Modes of Impulsivity in Parkinson's Disease. PLoS ONE, 2014, 9, e85747.	2.5	116
254	Seeing what you want to see: priors for one's own actions represent exaggerated expectations of success. Frontiers in Behavioral Neuroscience, 2014, 8, 232.	2.0	34
255	Beyond the "urge to move": objective measures for the study of agency in the post-Libet era. Frontiers in Human Neuroscience, 2014, 8, 450.	2.0	47
256	Dissociable mechanisms of speed-accuracy tradeoff during visual perceptual learning are revealed by a hierarchical drift-diffusion model. Frontiers in Neuroscience, 2014, 8, 69.	2.8	79
257	Characterizing mild cognitive impairment in incident Parkinson disease. Neurology, 2014, 82, 308-316.	1.1	359
258	The medial frontal-prefrontal network for altered awareness and control of action in corticobasal syndrome. Brain, 2014, 137, 208-220.	7.6	66
259	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain, 2014, 137, 2743-2758.	7.6	127
260	The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Annals of Neurology, 2014, 75, 829-836.	5.3	61
261	The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurology, 2014, 14, 204.	1.8	430
262	The neural signature of escalating frustration in humans. Cortex, 2014, 54, 165-178.	2.4	77
263	Direct Gaze Elicits Atypical Activation of the Theory-of-Mind Network in Autism Spectrum Conditions. Cerebral Cortex, 2014, 24, 1485-1492.	2.9	81
264	R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimer's and Dementia, 2014, 10, 602.	0.8	94
265	The default mode network is disrupted in parkinson's disease with visual hallucinations. Human Brain Mapping, 2014, 35, 5658-5666.	3.6	138
266	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
267	Selection and stopping in voluntary action: A meta-analysis and combined fMRI study. Neurolmage, 2014, 86, 381-391.	4.2	123
268	The white elephant revived: A new marriage between PET and MRI. Neurolmage, 2014, 84, 1104-1106.	4.2	3
269	Cognition in corticobasal syndrome and progressive supranuclear palsy: A review. Movement Disorders, 2014, 29, 684-693.	3.9	137
270	Targeting impulsivity in Parkinson's disease using atomoxetine. Brain, 2014, 137, 1986-1997.	7.6	116

#	ARTICLE	IF	CITATIONS
271	Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain, 2014, 137, 1145-1155.	7.6	113
272	The binaural masking level difference: cortical correlates persist despite severe brain stem atrophy in progressive supranuclear palsy. Journal of Neurophysiology, 2014, 112, 3086-3094.	1.8	17
273	Cue integration and the perception of action in intentional binding. Experimental Brain Research, 2013, 229, 467-474.	1.5	109
274	Serotonin 2A receptors contribute to the regulation of risk-averse decisions. NeuroImage, 2013, 83, 35-44.	4.2	36
275	Playing it safe but losing anyway—Serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion. European Neuropsychopharmacology, 2013, 23, 919-930.	0.7	39
276	Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent Than Expected in the UK Population. American Journal of Human Genetics, 2013, 92, 345-353.	6.2	297
277	Imaging Psychogenic Movement Disorders. Current Neurology and Neuroscience Reports, 2013, 13, 402.	4.2	15
278	Different Neural Mechanisms within Occipitotemporal Cortex Underlie Repetition Suppression across Same and Different-Size Faces. Cerebral Cortex, 2013, 23, 1073-1084.	2.9	54
279	Reorganisation of brain networks in frontotemporal dementia and progressive supranuclear palsy. NeuroImage: Clinical, 2013, 2, 459-468.	2.7	41
280	Coactivation sign in fixed dystonia. Parkinsonism and Related Disorders, 2013, 19, 474-476.	2.2	8
281	Serotonin 2A Receptors, Citalopram and Tryptophan-Depletion: a Multimodal Imaging Study of their Interactions During Response Inhibition. Neuropsychopharmacology, 2013, 38, 996-1005.	5.4	41
282	Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropsychopharmacology, 2013, 64, 490-495.	4.1	121
283	The functional neuroimaging correlates of psychogenic versus organic dystonia. Brain, 2013, 136, 770-781.	7.6	83
284	Perseveration and Choice in Parkinson's Disease: The Impact of Progressive Frontostriatal Dysfunction on Action Decisions. Cerebral Cortex, 2013, 23, 1572-1581.	2.9	31
285	The Impact of Neurodegeneration on Network Connectivity: A Study of Change Detection in Frontotemporal Dementia. Journal of Cognitive Neuroscience, 2013, 25, 802-813.	2.3	47
286	The size, burden and cost of disorders of the brain in the UK. Journal of Psychopharmacology, 2013, 27, 761-770.	4.0	163
287	The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 544-551.	1.9	94
288	DOPAMINE TRANSPORTER (DAT) IMAGING CAN BE NORMAL WITH NEUROPATHOLOGICALLY CONFIRMED CORTICOBASAL DEGENERATION. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.59-e2.	1.9	3

#	ARTICLE	IF	CITATIONS
289	Finding and Feeling the Musical Beat: Striatal Dissociations between Detection and Prediction of Regularity. <i>Cerebral Cortex</i> , 2013, 23, 913-921.	2.9	207
290	Acute serotonin 2A receptor blocking alters the processing of fearful faces in the orbitofrontal cortex and amygdala. <i>Journal of Psychopharmacology</i> , 2013, 27, 903-914.	4.0	20
291	Choosing the Rules: Distinct and Overlapping Frontoparietal Representations of Task Rules for Perceptual Decisions. <i>Journal of Neuroscience</i> , 2013, 33, 11852-11862.	3.6	71
292	A Longitudinal Study of Motor, Oculomotor and Cognitive Function in Progressive Supranuclear Palsy. <i>PLoS ONE</i> , 2013, 8, e74486.	2.5	24
293	Direction-Sensitive Codes for Observed Head Turns in Human Superior Temporal Sulcus. <i>Cerebral Cortex</i> , 2012, 22, 735-744.	2.9	31
294	Research paper does not show causal link between benzodiazepine use and diagnosis of dementia. <i>BMJ</i> , The, 2012, 345, e7984-e7984.	6.0	11
295	Effects of Acute Tryptophan Depletion on Prefrontal-Amygdala Connectivity While Viewing Facial Signals of Aggression. <i>Biological Psychiatry</i> , 2012, 71, 36-43.	1.3	128
296	Reversed Frontotemporal Connectivity During Emotional Face Processing in Remitted Depression. <i>Biological Psychiatry</i> , 2012, 72, 604-611.	1.3	55
297	The motor system and its disorders. <i>NeuroImage</i> , 2012, 61, 464-477.	4.2	52
298	White matter pathology in Parkinson's disease: The effect of imaging protocol differences and relevance to executive function. <i>NeuroImage</i> , 2012, 62, 1675-1684.	4.2	102
299	Selection and inhibition mechanisms for human voluntary action decisions. <i>NeuroImage</i> , 2012, 63, 392-402.	4.2	60
300	Social cognitive deficits and their neural correlates in progressive supranuclear palsy. <i>Brain</i> , 2012, 135, 2089-2102.	7.6	105
301	Functional biomarkers for neurodegenerative disorders based on the network paradigm. <i>Progress in Neurobiology</i> , 2011, 95, 505-509.	5.7	22
302	A Head View-Invariant Representation of Gaze Direction in Anterior Superior Temporal Sulcus. <i>Current Biology</i> , 2011, 21, 1817-1821.	3.9	103
303	Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity. <i>Neurobiology of Disease</i> , 2011, 43, 79-85.	4.4	52
304	Role of brain imaging in early parkinsonism. <i>BMJ: British Medical Journal</i> , 2011, 342, d638-d638.	2.3	4
305	Changes in "Top-Down" Connectivity Underlie Repetition Suppression in the Ventral Visual Pathway. <i>Journal of Neuroscience</i> , 2011, 31, 5635-5642.	3.6	101
306	Magnetoencephalography of frontotemporal dementia: spatiotemporally localized changes during semantic decisions. <i>Brain</i> , 2011, 134, 2513-2522.	7.6	25

#	ARTICLE	IF	CITATIONS
307	Parkinson's disease and healthy aging: Independent and interacting effects on action selection. Human Brain Mapping, 2010, 31, 1886-1899.	3.6	30
308	Connectivity analysis is essential to understand neurological disorders. Frontiers in Systems Neuroscience, 2010, 4, .	2.5	68
309	Conversion disorder: understanding the pathogenic links between emotion and motor systems in the brain. Brain, 2010, 133, 1295-1297.	7.6	15
310	Connectivity Analysis Reveals a Cortical Network for Eye Gaze Perception. Cerebral Cortex, 2010, 20, 1780-1787.	2.9	71
311	Neural activity associated with monitoring the oscillating threat value of a tarantula. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20582-20586.	7.1	294
312	Neural Abnormalities in Early-Onset and Adolescence-Onset Conduct Disorder. Archives of General Psychiatry, 2010, 67, 729.	12.3	179
313	Action selection: A race model for selected and non-selected actions distinguishes the contribution of premotor and prefrontal areas. NeuroImage, 2010, 51, 888-896.	4.2	67
314	The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease. Neurobiology of Aging, 2010, 31, 1064-1068.	3.1	37
315	Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment?. NeuroImage, 2010, 52, 1015-1026.	4.2	128
316	Feeling the Beat: Premotor and Striatal Interactions in Musicians and Nonmusicians during Beat Perception. Journal of Neuroscience, 2009, 29, 7540-7548.	3.6	473
317	What "Works" in Working Memory? Separate Systems for Selection and Updating of Critical Information. Journal of Neuroscience, 2009, 29, 13735-13741.	3.6	106
318	The neural basis of effective memory therapy in a patient with limbic encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1202-1205.	1.9	51
319	Emotion recognition in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1143-1145.	1.9	60
320	Motor imagery after stroke: Relating outcome to motor network connectivity. Annals of Neurology, 2009, 66, 604-616.	5.3	247
321	Personality Predicts the Brain's Response to Viewing Appetizing Foods: The Neural Basis of a Risk Factor for Overeating. Journal of Neuroscience, 2009, 29, 43-51.	3.6	119
322	Cortical neuroplasticity in patients recovering from acute optic neuritis. NeuroImage, 2008, 42, 836-844.	4.2	14
323	Connectivity from the ventral anterior cingulate to the amygdala is modulated by appetitive motivation in response to facial signals of aggression. NeuroImage, 2008, 43, 562-570.	4.2	91
324	Action-blindsight in healthy subjects after transcranial magnetic stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1353-1357.	7.1	40

#	ARTICLE	IF	CITATIONS
325	How Does Reward Expectation Influence Cognition in the Human Brain?. Journal of Cognitive Neuroscience, 2008, 20, 1980-1992.	2.3	41
326	Parkinson's disease and dopaminergic therapyâ€™ differential effects on movement, reward and cognition. Brain, 2008, 131, 2094-2105.	7.6	168
327	Rule-Selection and Action-Selection have a Shared Neuroanatomical Basis in the Human Prefrontal and Parietal Cortex. Cerebral Cortex, 2008, 18, 2275-2285.	2.9	55
328	Is the Prefrontal Cortex Necessary for Establishing Cognitive Sets?. Journal of Neuroscience, 2007, 27, 13303-13310.	3.6	57
329	An fMRI study of the neural correlates of graded visual perception. Neurolmage, 2006, 31, 1711-1725.	4.2	63
330	Aging is associated with contrasting changes in local and distant cortical connectivity in the human motor system. Neurolmage, 2006, 32, 747-760.	4.2	85
331	Generating animal and tool names: An fMRI study of effective connectivity. Brain and Language, 2005, 93, 32-45.	1.6	69
332	Frequency specific changes in regional cerebral blood flow and motor system connectivity following rTMS to the primary motor cortex. Neurolmage, 2005, 26, 164-176.	4.2	121
333	Motion or activity: their role in intra- and inter-subject variation in fMRI. Neurolmage, 2005, 26, 960-964.	4.2	208
334	The Prefrontal Cortex shows Context-specific Changes in Effective Connectivity to Motor or Visual Cortex during the Selection of Action or Colour. Cerebral Cortex, 2004, 15, 85-95.	2.9	114
335	Activations related to â€™mirrorâ€™ and â€™canonicalâ€™ neurones in the human brain: an fMRI study. Neurolmage, 2003, 18, 928-937.	4.2	661
336	Lateralized Cognitive Processes and Lateralized Task Control in the Human Brain. Science, 2003, 301, 384-386.	12.6	293
337	Patients with focal arm dystonia have increased sensitivity to slow-frequency repetitive TMS of the dorsal premotor cortex. Brain, 2003, 126, 2710-2725.	7.6	191
338	Acute Remapping within the Motor System Induced by Low-Frequency Repetitive Transcranial Magnetic Stimulation. Journal of Neuroscience, 2003, 23, 5308-5318.	3.6	262
339	Attention to action in Parkinsonâ€™s disease. Brain, 2002, 125, 276-289.	7.6	283
340	Changes of Cortico-striatal Effective Connectivity during Visuomotor Learning. Cerebral Cortex, 2002, 12, 1040-1047.	2.9	141
341	Active maintenance in prefrontal area 46 creates distractor-resistant memory. Nature Neuroscience, 2002, 5, 479-484.	14.8	346
342	Initial Demonstration of in Vivo Tracing of Axonal Projections in the Macaque Brain and Comparison with the Human Brain Using Diffusion Tensor Imaging and Fast Marching Tractography. Neurolmage, 2002, 15, 797-809.	4.2	171

#	ARTICLE	IF	CITATIONS
343	Attention to Action: Specific Modulation of Corticocortical Interactions in Humans. Neurolmage, 2002, 17, 988-998.	4.2	195
344	Parahippocampal Reactivation Signal at Retrieval after Interruption of Rehearsal. Journal of Neuroscience, 2002, 22, 6315-6320.	3.6	54
345	Dorsal Prefrontal Cortex: Maintenance in Memory or Attentional Selection?. , 2002, , 221-232.		14
346	Attention to action: specific modulation of corticocortical interactions in humans. Neurolmage, 2002, 17, 988-98.	4.2	61
347	Parahippocampal reactivation failure leads to forgetting independently of encoding failure. Neurolmage, 2001, 13, 734.	4.2	0
348	Working Memory for Location and Time: Activity in Prefrontal Area 46 Relates to Selection Rather than Maintenance in Memory. Neurolmage, 2001, 14, 77-86.	4.2	192
349	Imaging the mental components of a planning task. Neuropsychologia, 2001, 39, 315-327.	1.6	131
350	The Prefrontal Cortex: Response Selection or Maintenance Within Working Memory?. Science, 2000, 288, 1656-1660.	12.6	822
351	The impact of brain imaging technology on our understanding of motor function and dysfunction. Current Opinion in Neurobiology, 1999, 9, 728-734.	4.2	18
352	The effect of a history of conduct disorder in adult major depression. Journal of Affective Disorders, 1996, 37, 51-63.	4.1	26
353	Systemic idazoxan impairs performance in a non-reversal shift test: implications for the role of the central noradrenergic systems in selective attention. Journal of Psychopharmacology, 1996, 10, 188-194.	4.0	11
354	Inpatient general medicine is evidence based. Lancet, The, 1995, 346, 407-410.	13.7	374
355	A "Mini Linguistic State Examination"™ to Classify Primary Progressive Aphasia. SSRN Electronic Journal, 0, , .	0.4	1
356	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. SSRN Electronic Journal, 0, , .	0.4	1
357	Prefrontal cortex and attention to action. , 0, , 263-286.		4